MSB Charts, page-242

With little to hang there hat on MSB was discounted heavily by US funds during the Nasdaq Listing.

Pre- Nasdaq the closing price of the stock was around $3.40. I put it to you this should have been a more normal range and as we can see we are heading back to this. However, this time round the company is knocking on the door of FDA approval for RYONIL, has formed a billion dollar partnership with Grunenthal and has 2 major products knocking on the door of PHASE 3 trial readouts for CHF and BACK PAIN.

So when you assess Edisons valuation I believe its realistic as a 12 month target. Don't forget they have cash to see the above through and are a global leader

See we head into zone 2 and still at a big discount to Edsions valuation of $7.91 which is in zone 3. Zone 1 was a joke for me.